Market CompetitionSome investors are concerned about Rezdiffra losing market share to the more visible and popularized Wegovy treatment.
Market GrowthAnalysts believe the EU is unlikely to be a major growth driver for Madrigal, at least in the near term, due to slower European launch dynamics and pricing constraints.
Pricing And ReimbursementCost-conscious single payer systems in the EU may not reimburse Rezdiffra near its current annual Wholesale Acquisition Cost of approximately $49k.